Jon H Chung
Overview
Explore the profile of Jon H Chung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhangoo M, Costantini C, Clifford B, Chung J, Schrock A, Ali S, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-7.
PMID: 35172493
No abstract available.
2.
Pal S, Ali S, Ross J, Choueiri T, Chung J
JCO Precis Oncol
. 2022 Feb;
1:1-5.
PMID: 35172492
No abstract available.
3.
Powell S, Dib E, Bleeker J, Keppen M, Mazurczak M, Hack K, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-12.
PMID: 35135120
Introduction: Precision oncology (PO) is a growing treatment approach in the era of next-generation sequencing (NGS) and matched therapies. Effective delivery of PO in the community has not been extensively...
4.
Lee J, Hazar-Rethinam M, Decker B, Gjoerup O, Madison R, Lieber D, et al.
Clin Cancer Res
. 2021 Nov;
28(4):728-737.
PMID: 34753780
Purpose: Oncogenic kinase fusions are targetable with approved and investigational therapies and can also mediate acquired resistance (AR) to targeted therapy. We aimed to understand the clinical validity of liquid...
5.
Riess J, Rahman S, Kian W, Edgerly C, Heilmann A, Madison R, et al.
Transl Oncol
. 2021 Aug;
14(10):101184.
PMID: 34333275
Background: The translocation t(15:19) produces the oncogenic BRD4-NUT fusion which is pathognomonic for NUT carcinoma (NC), which is a rare, but extremely aggressive solid tumor. Comprehensive genomic profiling (CGP) by...
6.
Bratslavsky G, Gleicher S, Jacob J, Sanford T, Shapiro O, Bourboulia D, et al.
Urol Oncol
. 2021 Mar;
39(6):367.e1-367.e5.
PMID: 33775530
Introduction And Objective: Unlike clear cell renal cell carcinoma (CCRCC), collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are rare tumors that progress rapidly and appear resistant to current...
7.
Tukachinsky H, Madison R, Chung J, Gjoerup O, Severson E, Dennis L, et al.
Clin Cancer Res
. 2021 Feb;
27(11):3094-3105.
PMID: 33558422
Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to bone, making tissue biopsies challenging to obtain. We...
8.
Sheikine Y, Pavlick D, Klempner S, Trabucco S, Chung J, Rosenzweig M, et al.
JCO Precis Oncol
. 2020 Sep;
2.
PMID: 32913992
Purpose: Dabrafenib and trametinib are approved for the management of advanced non-small-cell lung cancers (NSCLCs) that harbor V600E mutations. Small series and pan-cancer analyses have identified non-V600 alterations as therapeutic...
9.
Sokol E, Pavlick D, Khiabanian H, Frampton G, Ross J, Gregg J, et al.
JCO Precis Oncol
. 2020 Sep;
4:442-465.
PMID: 32903788
Purpose: BRCA1 or BRCA2 loss of function results in homologous recombination deficiency (HRD), which is targetable by poly (ADP-ribose) polymerase (PARP) inhibitors and other DNA-damaging agents. In cancers associated with...
10.
Necchi A, Madison R, Pal S, Ross J, Agarwal N, Sonpavde G, et al.
Eur Urol Focus
. 2020 Aug;
7(6):1339-1346.
PMID: 32861617
Background: Characterization of the different genomic alterations (GAs) in urothelial carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and inform distinct putative pathogenetic mechanisms. Objective: To describe...